Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM-NK: CAR-NK Cell Therapy in Advanced Solid Tumors
NCT07510828Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of EB-PT-CAR-NK-S and EB-PT-CAR-NK-D in solid tumor (advanced stage) (2 arms), sponsored by Biotech Pharmaceutical. Primary endpoint: Dose-limiting toxicities at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
EB-PT-CAR-NK-SEB-PT-CAR-NK-D
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07510828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510828.